What to know about sickle cell anemia or sickle cell disease ranging from cause, symptoms and treatment


Sickle cell anemia or Sickle cell disease (SCD), is a systemic disorder caused by a mutation in the gene encoding the β chain of hemoglobin.

This mutation leads to the production of sickle hemoglobin HbS.

Sickled red blood cells were first observed in 1910 by JB Herrick in a Black West Indian student.

INTRODUCTION



Sickle cell anemia or Sickle cell disease is the result of a single base-pair change, thymine for adenine , at the sixth codon of the beta gene.

in which the change encodes Valine instead of glutamine in the sixth position on the beta globin molecule.

Beta globin haplotypes are the different DNA structures associated with the sickle gene are identified by a pattern of restriction enzyme sites.

Therefore, it is important to note that HbS gene is prevalent in malaria-endemic regions , distribution is however world-wide, with the greatest incidence in tropical Africa.

It occurs in the USA, Middle East, India, the Caribbean, South and Central America, Turkey and throughout the Mediterranean region.

A 2009 study carried out in Nigeria showed that 2-3% of Nigerian newborns homozygous.

Incidence in the general Nigerian population is 1:300 with Frequency of the S gene in Nigeria is about 25% Mode of inheritance= autosomal recessive.

PATHOGENESIS


The hemoglobin molecule (alpha and beta globin subunits) picks up oxygen in the lungs, and releases it when the red cells reach peripheral tissues, such as the muscles in In Sickle cell anemia or Sickle cell disease.

And also, normal red cells maintain a basic disc shape, whether they are transporting oxygen or not but the case is different with sickled hemoglobin.

Sickle hemoglobin exists as isolated units in the red cells.

when they have oxygen bound, Whereas sickle hemoglobin releases oxygen in the peripheral tissues, however, the molecules tend to stick together and form long chains or polymers (polymerization).

These rigid polymers interact with the cell and cause it to bend out of shape Polymerized sickle hemoglobin does not form single strands.

But the molecules group in long bundles of 14 strands each that twist in a regular fashion, much like a braid.

In Sickle cell anemia or Sickle cell disease, most distorted cells are simply shaped irregularly, a few have a cresent-like appearence under the microscope.

These cresent-like or “sickle shaped” red cells gave the disorder its name.


A single red cell may traverse the circulation four times in one minute. Sickle hemoglobin undergoes repeated episodes of polymerization and depolymerization (sickle—unsickle cycle).

This cyclic alteration in the state of the molecules damages the hemoglobin and ultimately the red cell itself.
 Diameter of RBC =7microns
 Diameter of capillaries =3microns

Summary,


In
Sickle cell anemia or Sickle cell disease Polymers tend to grow from a single start site (nucleation site) and often grow in multiple directions. Star-shaped clusters of hemoglobin S polmers develop commonly.


Sickling occurs at the venous end of capillaries wh
ereas unsickling occurs at the arterial end.


Two essential pathological processes arise from sickling: Haemolysis and vaso-occlusion

The pathological features of SCD relate to the shortened life span of the sickled blood cells, (16-20 days rather than a lifespan of 120 days in normal red cells) which leads to haemolytic anemia

The mechanism is likely to be responsible for complications such as pulmonary hypertension and stroke.

Sickled cells directly cause Small vessel occlusion

Vaso-occlusion is the major cause of morbidity and mortality in sickle cell anemia, accompanied by occlusion of blood vessels followed by ischemia or infarction in various tissues, leading ultimately to progressive end organ damage.


The process of vaso-occlusion


It was first thought that hemoglobin S polymerization resulted in the entrapment of sickled, poorly deformable erythrocytes that mechanically blocked small caliber vessels.


Damage similar to that seen in patients with atherosclerotic vascular disease has been seen in the large cerebral vessels of patients with Sickle cell anemia or Sickle cell disease, including intimal hyperplasia, and fibroblast and smooth muscle proliferation.


It will be of great importance to consider these terms [CRISES]; Vaso-occlusive, Haemolytic , Aplastic and Acute sequestration.


VASO-OCCLUSIVE CRISIS


This crisis is due to obstruction of blood flow in the smaller venules , capillaries and even in medium-sized or large arteries, as a result of the increased viscosity and sludging associated with sickling.

Increased adhesiveness of sickled reticulocytes worsens occlusion. Vaso-occlusion is the pathophysiologic basis of most of the clinical.


HAEMOLYTIC CRISIS


Haemolytic crisis makes RBCs are broken down at a more rapid rate than during the steady state of the disease, it is precipitated by malaria and bacterial infections.

Features include:


*Severe anaemia, Cardiac failure
*Jaundice, hepatomegaly.
*Encephalopathy-seizures, altered sensorium
*The terms ‘haemolytic’ and ‘hyperhaemolytic’ are often used interchangeably, but the latter technically refers to co-existence of SCA and G6PD[glucose 6-phosphate dehydrogenase deficiency].
APLASTIC CRISIS

There is a shut down of the bone marrow which is usually limited to the red blood cell precursors, making the patient to become profoundly anemic and may go into high-output cardiac failure.

Anaemia reoccurs after blood transfusions, until the crisis is over, Several viruses are associated with this syndrome most especially parvovirus B19.

ACUTE SEQUESTRATION


The Pooling of blood in the spleen is a frequent occurrence in children with sickle cell anemia, particularly in the first few years of life, resulting in splenic sequestration crisis.

They are often associated with viral or bacterial infections; acute chest syndrome occurred in 20% in one series .

The usual clinical manifestations are sudden weakness, pallor, tachycardia, tachypnea, and abdominal fullness.

DIAGNOSIS SICKLE CELL ANEMIA
Clinical …….80% of cases.
Laboratory diagnosis:
Electrophoresis…cellulose acetate

DIAGNOSTIC METHODS INCLUDE:


Full blood count, blood film and reticulocyte count, bilirubin.
Hb electrophoresis using cellulose acetate or agar gel
High performance liquid chromatography (HPLC)
Isoelectric focussing (IEL)
Polymerase chain reaction (PCR)
Supplementary genetic tests

MANAGEMENT FOR A STEADY STATE


  • Determine and record physical/haematol Parameters.
    Avoid factors that encourage sickling.
    Folic acid supplementation.
    Malaria prophylaxis.
  • Always visit idealmedhealth for ideal answers and products
    Immunisation……pneumococcal , Hib and Hepatitis B

TREATMENTS


ANTISICKLING AGENTS

Hydroxycarbamide, formerly known as Hydroxyurea.

15mg/kg/24 hrs. gradually increase to max of 30mg/kg/24hrs. Monitor FBC, LFT and HbF. Increase in HbF is usually 10-15%
Trade name –Hydrea
*5-Azacytidine,
*decitibine
*Histone deacetylase inhibition: short-chain fatty acids –butyric acid.
*Recombinant human erythropoietin (rhEPO)


It is important to note that hydroxycarbamide is the most successful drug therapy for scd.

It is a cytotoxic and cytoreductase antimetabolite that acts via inhibition of DNA synthesis by inhibiting ribonucleotide reductase. Known pharmacological effects that may contribute to the drug’s efficacy in SCD include:

Hydroxycarbamide


1.increase in red cell content of Hb F.
2.dose related cytoreductase effects on neutrophils.
3.increase in water content of red cells.
4.increased deformability and successful microvascular navigation of sickled cells.
5.altered adhesion of RBCs to endothelium by decreasing the expression of endothelial adhesion molecules.
Treatment with hydroxycarbamide shows significant reduction in bone pain crises, admissions, and need for blood transfusion#


Gene therapy

The term gene therapy applied to any manoeuvre in which genes or genetically modified cells are introduced into a patient for therapeutic benefit.
Gene therapy corrects sickle cell disease in mice, scientists report
therapies designed to treat the genetic disease in humans.
The therapy transfers an anti-sickling variant of the faulty gene to the bone marrow, where it incorporates itself into the stem cells that give rise to red blood cells. In two mouse models, the new gene was rapidly expressed in 99 percent of all circulating red blood cells, preventing sickling and other signs of the disease, Leboulch said.

Antioxidant drugs mop up free radical or oxygen species that might lead to hemolysis..

One comment

Leave a Reply

Your email address will not be published. Required fields are marked *